CIDRAP newsletters options
Excess deaths substantially exceeded reported deaths from COVID-19 in many countries.
Europe's COVID-19 cases have dropped 60% in the past month, but progress is fragile.
"The CDC got the science right, but the policy and communication was really wrong."
The country continues to grapple with mask policies, and Emergent testifies at Congress about its J&J vaccine gaffe.
Patients in Malaysia hospitalized with pneumonia in 2017 and 2018 tested positive for the first human-infecting canine coronavirus.
One in seven US adult COVID-19 patients developed at least one new illness requiring medical care after recovery from their infection in 2020, finds an observational study yesterday in BMJ.
Antibiotic prescribing for young children in Israel sharply declined following implementation of pneumococcal conjugate vaccine (PCV), Israeli researchers reported today in Clinical Infectious Diseases.
Multisystem inflammatory syndrome has a different presentation in adults than in kids and may be missed.
For the first time in 14 months, most businesses in New York City can return to full capacity.
Argentina reports record deaths as activity continues to flare in places like Brazil, areas of Central America, and some Caribbean islands.
Long-haul COVID-19 was associated with severe or very severe symptoms, low income, and some age-groups, but was common even in those with mild symptoms, with a quarter of patients in that group having symptoms after 60 days, according to a Clinical Infectious Diseases study today that looked at adult Michigan patients.
CARB-X announced today that it is awarding Swiss drug maker Basilea Pharmaceutica International up to $2.7 million to develop a novel class of antibiotics to treat gram-negative bacterial infections.
Though the pandemic is ebbing in the US, those getting sick and hospitalized are skewing younger.
One study evaluates vaccine allocation plans, and the other reveals urban vs rural inequities.
The rate of multidrug-resistant organisms in organic meat was more than 50% lower than in conventional.
Some other Asian nations are facing their biggest surges of the pandemic, and 7 African nations report notable rises.
CARB-X announced today that it is awarding up to $4.1 million to Summit Therapeutics of Cambridge, Massachusetts, to develop a first-in-class antibiotic to treat multidrug-resistant bacterial infections.
Fewer high-risk outpatients with mild or moderate COVID-19 needed hospitalization or died within 28 days when given bamlanivimab soon after infection compared with their matched peers, finds an observational study yesterday in Open Forum Infectious Diseases.
For the first time since the pandemic started, all states are reporting declining cases.
Convalescent plasma did not improve survival or other important outcomes.
